C

CG Oncology Inc
NASDAQ:CGON

Watchlist Manager
CG Oncology Inc
NASDAQ:CGON
Watchlist
Price: 35.01 USD -0.4%
Market Cap: 2.3B USD
Have any thoughts about
CG Oncology Inc?
Write Note

Intrinsic Value

CGON's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one CGON stock under the Base Case scenario is 56.11 USD. Compared to the current market price of 35.01 USD, CG Oncology Inc is Undervalued by 38%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CGON Intrinsic Value
56.11 USD
Undervaluation 38%
Intrinsic Value
Price
C
Worst Case
Base Case
Best Case

Valuation Backtest
CG Oncology Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for CGON cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about CGON?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about CG Oncology Inc

Provide an overview of the primary business activities
of CG Oncology Inc.

What unique competitive advantages
does CG Oncology Inc hold over its rivals?

What risks and challenges
does CG Oncology Inc face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for CG Oncology Inc.

Provide P/S
for CG Oncology Inc.

Provide P/E
for CG Oncology Inc.

Provide P/OCF
for CG Oncology Inc.

Provide P/FCFE
for CG Oncology Inc.

Provide P/B
for CG Oncology Inc.

Provide EV/S
for CG Oncology Inc.

Provide EV/GP
for CG Oncology Inc.

Provide EV/EBITDA
for CG Oncology Inc.

Provide EV/EBIT
for CG Oncology Inc.

Provide EV/OCF
for CG Oncology Inc.

Provide EV/FCFF
for CG Oncology Inc.

Provide EV/IC
for CG Oncology Inc.

Show me price targets
for CG Oncology Inc made by professional analysts.

What are the Revenue projections
for CG Oncology Inc?

How accurate were the past Revenue estimates
for CG Oncology Inc?

What are the Net Income projections
for CG Oncology Inc?

How accurate were the past Net Income estimates
for CG Oncology Inc?

What are the EPS projections
for CG Oncology Inc?

How accurate were the past EPS estimates
for CG Oncology Inc?

What are the EBIT projections
for CG Oncology Inc?

How accurate were the past EBIT estimates
for CG Oncology Inc?

Compare the revenue forecasts
for CG Oncology Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of CG Oncology Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of CG Oncology Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of CG Oncology Inc compared to its peers.

Compare the P/E ratios
of CG Oncology Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing CG Oncology Inc with its peers.

Analyze the financial leverage
of CG Oncology Inc compared to its main competitors.

Show all profitability ratios
for CG Oncology Inc.

Provide ROE
for CG Oncology Inc.

Provide ROA
for CG Oncology Inc.

Provide ROIC
for CG Oncology Inc.

Provide ROCE
for CG Oncology Inc.

Provide Gross Margin
for CG Oncology Inc.

Provide Operating Margin
for CG Oncology Inc.

Provide Net Margin
for CG Oncology Inc.

Provide FCF Margin
for CG Oncology Inc.

Show all solvency ratios
for CG Oncology Inc.

Provide D/E Ratio
for CG Oncology Inc.

Provide D/A Ratio
for CG Oncology Inc.

Provide Interest Coverage Ratio
for CG Oncology Inc.

Provide Altman Z-Score Ratio
for CG Oncology Inc.

Provide Quick Ratio
for CG Oncology Inc.

Provide Current Ratio
for CG Oncology Inc.

Provide Cash Ratio
for CG Oncology Inc.

What is the historical Revenue growth
over the last 5 years for CG Oncology Inc?

What is the historical Net Income growth
over the last 5 years for CG Oncology Inc?

What is the current Free Cash Flow
of CG Oncology Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for CG Oncology Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
CG Oncology Inc

Balance Sheet Decomposition
CG Oncology Inc

Current Assets 563.9m
Cash & Short-Term Investments 552.9m
Receivables 182k
Other Current Assets 10.8m
Non-Current Assets 466k
PP&E 413k
Other Non-Current Assets 53k
Current Liabilities 11.9m
Accounts Payable 4.5m
Accrued Liabilities 7.2m
Other Current Liabilities 131k
Non-Current Liabilities 118k
Other Non-Current Liabilities 118k
Efficiency

Earnings Waterfall
CG Oncology Inc

Revenue
844k USD
Operating Expenses
-104.6m USD
Operating Income
-103.8m USD
Other Expenses
139k USD
Net Income
-103.6m USD

Free Cash Flow Analysis
CG Oncology Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

CGON Profitability Score
Profitability Due Diligence

CG Oncology Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Negative ROE
Negative Operating Income
Negative Net Income
24/100
Profitability
Score

CG Oncology Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

CGON Solvency Score
Solvency Due Diligence

CG Oncology Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
69/100
Solvency
Score

CG Oncology Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CGON Price Targets Summary
CG Oncology Inc

Wall Street analysts forecast CGON stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CGON is 69.07 USD with a low forecast of 52.52 USD and a high forecast of 90.3 USD.

Lowest
Price Target
52.52 USD
50% Upside
Average
Price Target
69.07 USD
97% Upside
Highest
Price Target
90.3 USD
158% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for CGON?

Click here to dive deeper.

Dividends

CG Oncology Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for CGON is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

CG Oncology Inc

Country

United States of America

Industry

Biotechnology

Market Cap

2.3B USD

Dividend Yield

0%

Description

CG Oncology Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Irvine, California and currently employs 61 full-time employees. The company went IPO on 2024-01-25. CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene is initially in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its lead candidate, BOND-003 is a targeted oncolytic intravesically delivered immunotherapy agent that is in Phase II for the treatment of Bacillus Calmette Guerin (BCG) unresponsive and intermediate risk NMIBC disease. Its other product candidate CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Contact

CALIFORNIA
Irvine
400 Spectrum Center Drive, Suite 2040
+19492886298
www.cgoncology.com

IPO

2024-01-25

Employees

61

Officers

Chairman & CEO
Mr. Arthur Kuan
President & COO
Mr. Ambaw Bellete M.S.
Chief Medical Officer
Dr. Vijay Kasturi M.D.
CFO & Secretary
Ms. Corleen M. Roche
Vice President of Finance, Accounting & Administration
Ms. Amy Steele
Chief Technical Officer
Mr. Swapnil Bhargava Ph.D.
Show More
General Counsel & Chief Compliance Officer
Mr. Joshua F. Patterson
Vice President of Corporate Development
Mr. Bing Kung
Show Less

See Also

Discover More
What is the Intrinsic Value of one CGON stock?

The intrinsic value of one CGON stock under the Base Case scenario is 56.11 USD.

Is CGON stock undervalued or overvalued?

Compared to the current market price of 35.01 USD, CG Oncology Inc is Undervalued by 38%.

Back to Top